Join
Live feed
·
PRReleasevia Quantisnow
MiNK Therapeutics Inc. logo

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

ByQuantisnow·Wall Street's wire, on your screen.
INKT· MiNK Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INKT (MiNK Therapeutics Inc.) and more on Quantisnow.